Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/j.pain.0000000000000628 http://scihub22266oqcxt.onion/10.1097/j.pain.0000000000000628 C4991564!4991564 !27537210     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27537210 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pain 2016 ; 157 (9 ): 2124-2140 Nephropedia Template TP {{tp|p=27537210 |t=2016. Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential |pdf=|usr=}}{{27537210 }} gab.com Text Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential JO: Pain http://www.kidney.de/pget.php?&tw=1&pmid=27537210 #FOAvip Uncoupling the protein-protein interaction between collapsin response mediator protein 2 (CRMP2) and N-type voltage-gated calcium channel (CaV2.2) with an allosteric CRMP2-derived peptide (CBD3) is antinociceptive in rodent models of inflammatory and neuropathic pain. We investigated the efficacy, duration of action, abuse potential, and neurobehavioral toxicity of an improved mutant CRMP2 peptide. A homopolyarginine (R9)-conjugated CBD3-A6K (R9-CBD3-A6K) peptide inhibited the CaV2.2-CRMP2 interaction in a concentration-dependent fashion and diminished surface expression of CaV2.2 and depolarization-evoked Ca influx in rat dorsal root ganglia neurons. In vitro studies demonstrated suppression of excitability of small-to-medium diameter dorsal root ganglion and inhibition of subtypes of voltage-gated Ca channels. Sprague-Dawley rats with tibial nerve injury had profound and long-lasting tactile allodynia and ongoing pain. Immediate administration of R9-CBD3-A6K produced enhanced dopamine release from the nucleus accumbens shell selectively in injured animals, consistent with relief of ongoing pain. R9-CBD3-A6K, when administered repeatedly into the central nervous system ventricles of naive rats, did not result in a positive conditioned place preference demonstrating a lack of abusive liability. Continuous subcutaneous infusion of R9-CBD3-A6K over a 24- to 72-hour period reversed tactile allodynia and ongoing pain, demonstrating a lack of tolerance over this time course. Importantly, continuous infusion of R9-CBD3-A6K did not affect motor activity, anxiety, depression, or memory and learning. Collectively, these results validate the potential therapeutic significance of targeting the CaV-CRMP2 axis for treatment of neuropathic pain. Twit Text FOAVip Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential ????Pain http://www.kidney.de/pget.php?&tw=1&pmid=27537210 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27537210 #FOAvip English Wikipedia <ref>{{Cite pmid|27537210 }}</ref> Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential #MMPMID27537210 Xie JY ; Chew LA ; Yang X ; Wang Y ; Qu C ; Wang Y ; Federici LM ; Fitz SD ; Ripsch MS ; Due MR ; Moutal A ; Khanna M ; White FA ; Vanderah TW ; Johnson PL ; Porreca F ; Khanna R Pain 2016[Sep]; 157 (9 ): 2124-2140 PMID27537210 show ga Uncoupling the protein-protein interaction between collapsin response mediator protein 2 (CRMP2) and N-type voltage-gated calcium channel (CaV2.2) with an allosteric CRMP2-derived peptide (CBD3) is antinociceptive in rodent models of inflammatory and neuropathic pain. We investigated the efficacy, duration of action, abuse potential, and neurobehavioral toxicity of an improved mutant CRMP2 peptide. A homopolyarginine (R9)-conjugated CBD3-A6K (R9-CBD3-A6K) peptide inhibited the CaV2.2-CRMP2 interaction in a concentration-dependent fashion and diminished surface expression of CaV2.2 and depolarization-evoked Ca influx in rat dorsal root ganglia neurons. In vitro studies demonstrated suppression of excitability of small-to-medium diameter dorsal root ganglion and inhibition of subtypes of voltage-gated Ca channels. Sprague-Dawley rats with tibial nerve injury had profound and long-lasting tactile allodynia and ongoing pain. Immediate administration of R9-CBD3-A6K produced enhanced dopamine release from the nucleus accumbens shell selectively in injured animals, consistent with relief of ongoing pain. R9-CBD3-A6K, when administered repeatedly into the central nervous system ventricles of naive rats, did not result in a positive conditioned place preference demonstrating a lack of abusive liability. Continuous subcutaneous infusion of R9-CBD3-A6K over a 24- to 72-hour period reversed tactile allodynia and ongoing pain, demonstrating a lack of tolerance over this time course. Importantly, continuous infusion of R9-CBD3-A6K did not affect motor activity, anxiety, depression, or memory and learning. Collectively, these results validate the potential therapeutic significance of targeting the CaV-CRMP2 axis for treatment of neuropathic pain. |Action Potentials/drug effects [MESH] |Animals [MESH] |Anxiety/drug therapy/etiology [MESH] |Aptamers, Peptide/pharmacology/*therapeutic use [MESH] |Disease Models, Animal [MESH] |Dopamine/metabolism [MESH] |Electric Stimulation [MESH] |Exploratory Behavior/drug effects [MESH] |Female [MESH] |Ganglia, Spinal/cytology [MESH] |Hindlimb Suspension [MESH] |Hyperalgesia/drug therapy [MESH] |Intercellular Signaling Peptides and Proteins/*chemistry [MESH] |Maze Learning/drug effects [MESH] |Mice, Inbred C57BL [MESH] |Nerve Tissue Proteins/*chemistry [MESH] |Neuralgia/*drug therapy/pathology [MESH] |Nucleus Accumbens/drug effects/metabolism [MESH] |Pain Threshold/drug effects [MESH] |Rats [MESH] |Rats, Sprague-Dawley [MESH]Sustained relief of ongoing experimental neuropathic pain by a CRMP2 p(epmc).pdf DeepDyve Pubget Overpricing